10- NI-11

w Al

Express Mail No. <u>EV913329554US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

cation of: Michael A. Zeligs Confirmation No.: 2485

Serial No.: 10/765,792 Art Unit: 1618

Filed: January 26, 2004 Examiner: Ebrahim, Nabila G

For: Phytochemicals for the Attorney Docket No: 9439-016-999

Treatment of Endometriosis

STATEMENT OF THE SUBSTANCE OF THE INTERVIEW UNDER § 37 C.F.R. 1.133

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

Pursuant to 37 C.F.R.§ 1.133(b) and MPEP 713.04, Attorneys for Applicant submit this Statement of the Substance of the Interview in connection with the interview on October 3, 2007 between Examiner Nabila G. Ebrahim and Attorney for Applicant, Thomas E. Friebel, in connection with the above-identified application.

During the interview on October 3, 2007, Examiner Ebrahim and Mr. Friebel discussed the Applicant's September 26, 2007 response to the non-final Office Action mailed May 10, 2007 including the declaration of the inventor Dr. Michael Zeligs which presented evidence that the claimed invention had been reduced to practice prior to the publication date of the Liang reference. Examiner Ebrahim and Mr. Friebel also discussed support for the new claims suggested by the Examiner.

Accordingly, Attorneys for Applicant respectfully request entry of the foregoing remarks into the file history of the above-identified application and that the Patent Office issue a second substantive Office Action.

U.S. Serial No. 10/765,792 Page 2

It is believed that no fee is due in connection with the filing of this Statement. However, should the Patent Office determine that a fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Date: 11 - 13 - 07

Respectfully submitted,

29,258

` (R

Jones Day

222 East 41st Street

New York, New York 10017-6701

(212) 326-3811